159 related articles for article (PubMed ID: 32881630)
1. Development of Human CBF1-Targeting Single-Stranded DNA Aptamers with Antiangiogenic Activity
Tezuka-Kagajo M; Maekawa M; Ogawa A; Hatta Y; Ishii E; Eguchi M; Higashiyama S
Nucleic Acid Ther; 2020 Dec; 30(6):365-378. PubMed ID: 32881630
[TBL] [Abstract][Full Text] [Related]
2. BAZF, a novel component of cullin3-based E3 ligase complex, mediates VEGFR and Notch cross-signaling in angiogenesis.
Ohnuki H; Inoue H; Takemori N; Nakayama H; Sakaue T; Fukuda S; Miwa D; Nishiwaki E; Hatano M; Tokuhisa T; Endo Y; Nose M; Higashiyama S
Blood; 2012 Mar; 119(11):2688-98. PubMed ID: 22279058
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
Tie J; Desai J
Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
[TBL] [Abstract][Full Text] [Related]
4. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
5. Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells.
Higashimoto Y; Matsui T; Nishino Y; Taira J; Inoue H; Takeuchi M; Yamagishi S
Microvasc Res; 2013 Nov; 90():64-70. PubMed ID: 24012635
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.
Shibuya M
BMB Rep; 2008 Apr; 41(4):278-86. PubMed ID: 18452647
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
9. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
11. Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review).
Katoh M
Int J Mol Med; 2013 Oct; 32(4):763-7. PubMed ID: 23863927
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis in cancer - general pathways and their therapeutic implications.
Dimova I; Popivanov G; Djonov V
J BUON; 2014; 19(1):15-21. PubMed ID: 24659637
[TBL] [Abstract][Full Text] [Related]
13. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
14. Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model.
Chauvet N; Romanò N; Lafont C; Guillou A; Galibert E; Bonnefont X; Le Tissier P; Fedele M; Fusco A; Mollard P; Coutry N
Int J Cancer; 2017 May; 140(9):2150-2161. PubMed ID: 28152577
[TBL] [Abstract][Full Text] [Related]
15. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
Gao J; Hu H; Wang X
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
[TBL] [Abstract][Full Text] [Related]
16. RBPJ/CBF1 interacts with L3MBTL3/MBT1 to promote repression of Notch signaling via histone demethylase KDM1A/LSD1.
Xu T; Park SS; Giaimo BD; Hall D; Ferrante F; Ho DM; Hori K; Anhezini L; Ertl I; Bartkuhn M; Zhang H; Milon E; Ha K; Conlon KP; Kuick R; Govindarajoo B; Zhang Y; Sun Y; Dou Y; Basrur V; Elenitoba-Johnson KS; Nesvizhskii AI; Ceron J; Lee CY; Borggrefe T; Kovall RA; Rual JF
EMBO J; 2017 Nov; 36(21):3232-3249. PubMed ID: 29030483
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic Potential of Microbial Metabolite Elaiophylin for Targeting Tumor Angiogenesis.
Lim HN; Jang JP; Han JM; Jang JH; Ahn JS; Jung HJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498688
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase D2 and heat shock protein 90 beta are required for BCL6-associated zinc finger protein mRNA stabilization induced by vascular endothelial growth factor-A.
Miwa D; Sakaue T; Inoue H; Takemori N; Kurokawa M; Fukuda S; Omi K; Goishi K; Higashiyama S
Angiogenesis; 2013 Jul; 16(3):675-88. PubMed ID: 23515950
[TBL] [Abstract][Full Text] [Related]
19. Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors.
Lassoued W; Murphy D; Tsai J; Oueslati R; Thurston G; Lee WM
Cancer Biol Ther; 2010 Dec; 10(12):1326-33. PubMed ID: 21079419
[TBL] [Abstract][Full Text] [Related]
20. Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60.
Yang J; Wang Q; Qiao C; Lin Z; Li X; Huang Y; Zhou T; Li Y; Shen B; Lv M; Feng J
Cell Mol Immunol; 2014 May; 11(3):285-93. PubMed ID: 24608894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
